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Abstract  
_____________________________________________________________________  
 
Ménière’s disease (MD) is an idiopathic inner ear disorder, characterised by 
episodes of vertigo, tinnitus, sensorineural hearing loss, and aural fullness in the 
affected ear.  The relatively high variability of symptomological changes renders it 
difficult to confirm the MD diagnosis.  The purpose of this study is to compare the 
diagnostic power of an instrumental method, electrocochleography (ECochG), and 
two subjective methods, including the criteria based on the clinical guidelines 
provided by the American Academy of Otolaryngology-Head and Neck Surgery 
Committee on Hearing Equilibrium (AAO-HNS CHE) and Gibson’s Score. 
A quota sampling method was used to include subjects.  A total of 250 
potential MD patients who were referred to the Department of Otolaryngology at the 
Christchurch Hospital between year 1994 and 2009 have had their signs and 
symptoms documented and ECochG testing completed.  A selection of details 
obtained from both AAO-HNS CHE and ECochG assessment results were examined 
as a chart review in regard to its function as a diagnostic tool for MD.   
The between-method reliability was found to be high, with a few 
disagreements on individual diagnosis.  Based on a receiver operating characteristic 
(ROC) curve analysis, the ECochG measures were shown to be pertinent to the 
diagnosis of MD.  It was also found that patients tested “positive”, as compared with 
those tested “negative”, tended to show higher correlations among the four key 
symptoms of MD and among the ECochG measures derived from the auditory evoked 
responses to tone bursts at frequencies in close proximity to each other.   
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Chapter One:  Introduction 
_____________________________________________________________________  
 
This study concerns the agreement on the diagnosis of Ménière’s disease 
(MD) between an instrumental measure, electrocochleography (ECochG), and two 
subjective measures, including the clinical guidelines specified by the American 
Academy of Otolaryngology-Head and Neck Surgery Committee on Hearing 
Equilibrium (AAO-HNS CHE) and the Gibson scale.  This chapter provides an 
overview of the rationale behind the investigation, a literature review, the research 
question, its importance and related aims and hypotheses. 
1.1  Overview 
Ménière’s disease is an idiopathic inner ear disorder (Menière, 1861; Ries, 
Rickert, & Schlauch, 1999).  It is characterised by episodes of vertigo, roaring 
tinnitus, fluctuating sensorineural hearing loss, and a sense of aural fullness in the 
affected ear, with a combination of these signs and symptoms fluctuating over months 
and years (Sajjadi & Paparella, 2008).  Vertigo can be experienced in two ways, with 
the sensation of oneself spinning through space being referred to as “subjective 
vertigo” and that of the environment spinning around oneself as “objective vertigo” 
(Bhatnagar, 2002).  Episodes of vertigo which can last for several minutes or hours 
are often associated with nausea and vomiting (Hall, 2007).  Fluctuating tinnitus and 
sensations of fullness in the ear can worsen during vertigo attacks (Valente, 
Hosoford-Dunn, & Roeser, 2008).  These symptoms may fluctuate in frequency and 
severity for different individuals, resulting in difficulties in the diagnosis of MD.   
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The aetiology of MD has been linked to endolymphatic hydrops, with 
evidence from histological studies (Hallpike & Cairns, 1938; Horner, 1991).  
Endolymphatic hydrops refers to swelling of cochlea at the boundaries of the scala 
media from excessive accumulation of the endolymph (Hall, 2007).  Treatment of MD 
can be difficult and controversial because the exact aetiology of MD is unknown and 
a complete remedy has not been developed.  Several treatment options are available 
depending on an individual’s symptoms and responses to previous treatments.  
Lifestyle changes, such as a low salt diet and avoidance of tobacco products, caffeine, 
alcohol, and chocolate, may be made to alleviate the symptoms before the 
administration of drugs and surgical intervention (Sajjadi & Paparella, 2008).   
Although MD has been extensively studied clinically and experimentally, little 
is known about the precise pathophysiology.  The diagnosis of MD is normally made 
using the clinical guidelines set by the AAO-HNS CHE based on a selection of signs 
and symptoms (Members of the Committee on Hearing and Equilibrium, 1995).  
Other measurements, such as Gibson’s Score, electrocochleography, and more 
recently, magnetic resonance imaging (MRI), have also been used to assist in the 
diagnosis of MD (Gibson, 1990; Nakashima et al., 2009).  However, the histological 
information and thus the confirmation of a MD diagnosis can only be obtained 
through post-mortem biopsies (Roeser, Valente, & Hosford-Dunn, 2000).  Therefore, 
the administration of appropriate clinical diagnostic tools and treatment remains a 
challenging task. 
1.2  Literature Review 
This literature review provides the theoretical framework and previous 
findings regarding a variety of approaches in the diagnosis of MD.  Specifically, this 
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review covers topics related to MD, AAO-HNS CHE criteria, Gibson’s Score, 
ECochG, and MRI of the inner ear. 
1.2.1  Ménière’s Disease (MD) 
In 1861, Prosper Ménière described the typical characteristics of MD 
(Menière, 1861; Morrison, 1997; Thorp & James, 2005; Sajjadi & Paparella, 2008; 
Vrabec, Simon, & Coker, 2007) based on the work of Pierre Flourens, along with his 
own observations of patients with vertigo, hearing loss, and tinnitus.  Pierre Flourens 
surgically removed the semicircular canals in a pigeon and found the removal resulted 
in a loss of balance that was oriented in the same direction as the removed 
semicircular canal (Baloh, 2001; Flourens, 1824; Thorp & James, 2005).  Although 
not well received at the time, Prosper Ménière concluded that the main clinical signs 
and symptoms of MD were tinnitus, progressive hearing loss, and vertigo attacks, and 
the cause was likely to be a lesion located in the semicircular canals (Thorp & James, 
2005; Sajjadi & Paparella, 2008).   
1.2.1.1  Aetiology and Prevalence 
The aetiology of MD has been studied extensively.  According to Horner 
(1993), endolymphatic hydrops was first discovered in the temporal bones of MD 
patients by Hallpike and Cairns (1938), who coined the term “endolymphatic 
hydrops” in referring to a swelling (edema) of the scala media within the cochlea 
(Hall, 2007).  It has been hypothesized that the cause of the swelling was either 
endolymphatic pressure or the K
+
 intoxication of the perilymph from the endolymph 
(Horner, 1991).  Horner (1991) surgically induced endolymphatic hydrops in guinea 
pigs to investigate the effects and found both hypotheses equally plausible.  
According to Horner (1993), many studies with similar experimental trials have been 
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conducted on different animals but none have proven a definitive cause of the edema 
of the scala media within the cochlea.  
Several estimates of the prevalence of MD have been published.  These results 
vary broadly depending on the population studied.  An estimated 513 per 100,000 was 
reported for a Finnish population (Havia, Kentala & Pyykkö, 2005) and 17 per 
100,000 for a homogeneous Asian population (Watanabe et al., 1995).  The large 
variations on the estimated prevalence across countries may be due to the between-
study differences in the information available at the time of the research, the way 
subjects were assessed and selected, cultural and therefore lifestyle differences and 
the average age of the populations of concern (Havia, Kentala & Pyykkö, 2005).  
Although the prevalence of MD is generally considered unknown (Costa, Sousa & 
Piza, 2002), Paparella, da Costa, Fox & Yoo (1991) noted that MD was more 
common in adults in their fourth or fifth decade of life.  Vrabec, Simon, & Coker 
(2007), in studying the prevalence of definite MD cases based on a review of the 
medical records of patients seen between 2001-2003 in a hospital in the USA 
(Houston, Texas), also concluded from the identified 190 MD cases that the mean age 
of onset for MD was 45.9 years of age.   
In summary, researchers have been generally consistent in the findings of the 
mean age of onset of MD, as well as the association between MD and endolymphatic 
hydrops and various risk factors, while the prevalence and the underlying 
pathophysiology of MD remain largely unclear. 
1.2.1.2  Audiometric Configuration 
Hearing loss in those with MD often occurs unilaterally but can also occur 
bilaterally (Thorp & James, 2005).  Sensorineural hearing loss (SNHL) was found to 
fluctuate in the early stages of MD, with the loss typically starting from low 
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frequencies.  After 8-10 years from onset, the hearing loss usually stabilizes at a 
moderate to severe sensorineural hearing loss (Vrabec, Simon, & Coker, 2007).  
Audiometric configuration has been studied in relation to endolymphatic hydrops, a 
major feature of MD (Horner, 1991).  For example, Horner (1993) found in guinea 
pigs that induced endolymphatic hydrops resulted in a peaked audiometric 
configuration.  The loss of hearing sensitivity was found to start at low frequencies, 
progress to high frequencies, showing a mid frequency ‘peak’ in the audiogram, and 
finally include mid frequencies at a later stage.  In a retrospective study, Ries, Rickert 
and Schlauch (1999) compared the audiometric configurations of individuals with 
unilateral MD, those with unilateral acoustic tumor, and those from a general clinical 
population of an audiology clinic.  It was found that 17% (13.6/80) of the participants 
with unilateral MD showed a peaked audiometric configuration in one ear and flat 
audiometric configuration in the other.  In comparison, 12.5% (7/56) of participants 
with unilateral acoustic tumor and 9% (8/89) of participants in the general clinical 
population also presented with a peaked audiometric configuration.  This finding 
indicated that individuals with MD had a higher incidence of peaked audiometric 
configuration but it could not be concluded that the peaked audiometric configuration 
was pathognomonic of MD.  Furthermore, McNeill, Cohen and Gibson (2009) 
examined the hearing change of six individuals with MD before, during and after 
attacks of vertigo.  The study showed that five of the subjects showed less than a 10 
dBHL change in their audiometric hearing threshold at all frequencies tested before, 
during and after an attack of vertigo.  One patient showed some deterioration of 
hearing before the vertigo attack only.  It was, therefore, suggested that hearing 
thresholds did not alter significantly before, during or after vertigo attacks for 
individuals with MD. 
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1.2.2  Subjective Assessment of MD 
Several methods can be used to assist in the assessment of individuals with 
MD.  In common practice, a subjective assessment following AAO-HNS CHE criteria 
or the Gibson scale is used for the diagnosis of MD.  For diagnostic purpose, these 
subjective assessment methods can be used on their own or in combination with an 
instrumental approach, such as ECochG measures.   
1.2.2.1  AAO-HS CHE Criteria 
The AAO-NHS CHE approach to the diagnosis of MD is summarised in a set 
of guidelines that were published to standardise the diagnostic criteria.  These 
guidelines were first published in 1972, and then revised in 1985 and 1995 
(Committee on Hearing and Equilibrium, 1972; Committee on Hearing and 
Equilibrium, 1985; Members of the Committee on Hearing and Equilibrium, 1995). 
1.2.2.1.1  The AAO-HS CHE Guidelines 
In 1972, the first standard for MD diagnosis was established by the American 
Academy of Otolaryngology-Head and Neck Surgery Committee on Hearing and 
Equilibrium using a letter designation system to categorize various forms of patient 
presentations.  The categorization of this method is based on the consistency of the 
presence of vertigo spells in relation to hearing status (Committee on Hearing and 
Equilibrium, 1972).  The four categories with their associated descriptions are shown 
in Table 1.  In 1985, the AAO-NHS CHE guidelines for the diagnosis of MD were 
revised as there were several suggestions made to improve the reporting of the 
symptoms.  Instead of employing only qualitative descriptors as in the previous 
criteria, this revision incorporated the use of a formula to reflect the change of vertigo 
spells with the frequency of the vertigo attack taken into consideration (Committee on 
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Hearing and Equilibrium, 1985).  The formula expresses the effect that treatment has 
on the vertigo spells.  A ratio of the average number of vertigo attacks per month for a 
24 month period following initial treatment to that for a 6 month period before 
treatment is calculated.  Hearing is assessed using a four-frequency pure tone average 
(PTA) at 500 Hz, 1 kHz, 2 kHz, and 3 kHz.  A change in hearing is determined by 
comparing pre and post-treatment PTA values.  Finally, the degree of disability 
caused by the disease in the affected individual was noted both before and after 
treatment.  The formula and the criteria set for different degrees of disability are 
shown in Table 2.  
 
Table 1.   The 1972 AAO-HNS Criteria for the diagnosis of Ménière’s disease (adapted from 
Committee on Hearing and Equilibrium, 1972; p. 1464). 
  
 Class  Criteria 
  
 A - Absence of definitive spells for described period (in addition, absence  
  of adjunctive spells as well could be so noted) 
  - Hearing improved (in addition, hearing improved as well as serviceable  
  could be so noted) 
 
 B - Absence of definitive spells for described period 
  - Hearing unchanged 
 
 C - Absence of definitive spells for described period 
 - Hearing worse 
 
 D - Failure of control of definitive spells 
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Table 2.   The 1985 AAO-HNS Criteria for the diagnosis of Ménière’s disease (adapted from 
Committee on Hearing and Equilibrium, 1985; p. 6-7). 
  
Formula 
A = average number of definitive spells per month (24 mos. after therapy) 
B = average number of definitive spells per month (6 mos. before therapy) 
 (A÷ B) x 100 = numerical value 
 
umerical Value 
 0 = complete control of definitive spells 
 1-40 = substantial control of definitive spells 
 41-80 = limited control of definitive spells 
 80-120 = insignificant control of definitive spells 
 120 = worse (poorer) control of definitive spells 
 
Disability 
• No disability 
• Mild disability – intermittent or continuous dizziness/unsteadiness that 
precludes working in a hazardous environment 
• Moderate disability – intermittent or continuous dizziness/unsteadiness 
that results in a sedentary occupation, i.e. desk work 
• Severe disability – symptoms so severe that exclude gainful 
employment 
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In 1995, the AAO-NHS CHE guidelines were again revised in order to reflect 
the advancement in the knowledge gained from the research on MD.  These 
guidelines have been used to this date.  As shown in Table 3 below, The 1995 AAO-
NHS CHE guideline classified the diagnosis of MD into four levels: “possible”, 
“probable”, “definite”, and “certain” (Members of the Committee on Hearing and 
Equilibrium, 1995).  For a person to be diagnosed as having “possible” MD, they 
must have all other possible causes of vertigo excluded and have experienced either 
an episode of vertigo of the Ménière type, which is spontaneous rotational vertigo 
lasting for 20 minutes or greater (may be hours), often prostrating and accompanied 
by disequilibrium which may last for days.  Nausea is common and horizontal or 
horizontal rotatory nystagmus is always present.  The patient must also have no 
audiometrically established hearing loss or a fluctuating or fixed sensorineural hearing 
loss with disequilibrium but without definitive episodes.  For “probable” MD, the 
person must show one episode of vertigo, audiometrically established sensorineural 
hearing loss on at least one occasion, and tinnitus or aural fullness in the affected ear, 
with all other possible causes of the vertigo excluded.  For “definite” MD, the person 
must have two or more impulsive episodes of vertigo that last for at least 20 minutes 
in duration as well as audiometrically established sensorineural hearing loss on at 
least one occasion, and tinnitus or aural fullness during episodes of vertigo in the 
affected ear, with all other possible causes of the vertigo excluded.  Finally, to have a 
diagnosis of “certain” MD, the person must have presented with definite MD and 
have post-mortem histopathologic confirmation. 
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Table 3.   The 1995 AAO-HNS Criteria for the diagnosis of Ménière’s disease (adapted from 
Members of the Committee on Hearing and Equilibrium, 1995; p. 182). 
  
 Category Criteria 
  
“Possible”  - Episodic vertigo of the Ménière type without documented hearing  
   loss, or 
- Sensorineural hearing loss, fluctuating or fixed, with disequilibrium  
   but without definitive episodes  
- Other causes excluded 
 
“Probable” - One definitive episode of vertigo 
 - Audiometrically documented hearing loss on at least one occasion 
 - Tinnitus or aural fullness in the treated ear 
 - Other causes excluded 
 
“Definite”  - Two or more definitive spontaneous episodes of vertigo 20 minutes  
   or longer 
- Audiometrically documented hearing loss on at least one occasion 
- Tinnitus or aural fullness in the treated ear 
- Other causes excluded 
 
“Certain”  - Definite Ménière’s disease, plus histopathologic confirmation 
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1.2.2.1.2  Assessment of the AAO-HS CHE Guidelines 
The AAO-HNS CHE guidelines were designed to be used to formally 
document and diagnose MD in a patient to allow for appropriate treatment selection.  
The AAO-HNS CHE foundation employed evidence from the clinical research in the 
area of MD in the attempt to develop the best possible methods that are quantitative 
and reproducible in the assessment of diagnostic criteria (Monsell, 2005).  A review 
on the MD literature by Thorp, Shehab, Bance, and Rutka (2003) showed that 79.9% 
of papers reviewed reported the use of the AAO-HNS CHE criteria in the diagnosis of 
MD.  However, it was found that only 50% of those publications used the AAO-HNS 
CHE criteria correctly to diagnose MD.  This finding revealed concerns about the way 
this criterion has been used clinically to diagnose a patient with MD and the accuracy 
of diagnosis made for some patients.  Also, it has been noted that in reviewing clinical 
studies of MD, data is less comparable between studies if the AAO-HNS CHE criteria 
are not strictly adhered to (Stapleton & Mills, 2008).  
Van de Heyning et al. (1997) assessed the 1995 AAO-HNS CHE criteria with 
a method called the Inner Ear Profile.  The Inner Ear Profile, which was applicable to 
several inner ear disorders, included several subscales for different symptoms, 
quantifying a symptom without linking it to a specific diagnosis.  Questions were 
raised regarding the validity and the added value of self-administered questionnaires 
such as the AAO-HNS CHE criteria and the Gibson Scale.  Several conclusions were 
drawn from the assessment of the AAO-HNS CHE criteria.  Firstly, it was pointed out 
that the AAO-HNS CHE method was restricted, as it only diagnosed MD when a 
patient might have similar symptoms but a different diagnosis.  Secondly, the criteria 
noted some critical symptoms but did not take into account some details about the 
symptoms, such as the length of vertigo attacks and the severity of tinnitus and aural 
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pressure.  Finally, the criteria were criticized as not showing the impact hearing loss 
had on the individual as a disability.  In contrast, the Inner Ear Profile was shown to 
take these key measures into account when taking the symptoms of the patient.  It was 
concluded that the 1995 AAO-HNS CHE guidelines were limited in the scope of 
symptom investigations for the diagnosis of MD.  
A similar study by Stapleton and Mills (2008) compared the AAO-HNS CHE 
criteria to Prosper Ménière’s original description of the disease.  According to Prosper 
Ménière, patients who had symptoms of intermittent vertiginous episodes lasting for 
several minutes, along with tinnitus, aural fullness, and changes in hearing, could be 
diagnosed as having MD.  It was found that there were three times more patients 
diagnosed with MD using the AAO-HNS CHE criteria, 20.8% (135/650), than using 
Prosper Ménière’s original description of the disease, 6.9% (45/650).  This finding 
indicated that the AAO-HNS CHE method was more sensitive and less specific than 
the original description in the diagnosis of MD.   
1.2.2.2  Gibson’s Score 
Gibson’s Score is a points system developed in 1991 by William Gibson 
(Gibson, 1990).  Gibson (1990) established this method to simplify the diagnosis by 
looking at the interaction and dependence of the four typical components present in 
those with MD.  These four components are: vertigo, hearing, tinnitus, and aural 
fullness.  The score is designed to be used with the clinical history of the patient, not 
on the symptoms of the patient at the time of consultation.  Each of these four 
parameters included two (for tinnitus and aural fullness) or three descriptions (for 
vertigo and hearing) of symptoms for the parameter.  Each description is worth one 
point.  When a description applies to a patient, a point is given.  As shown in Table 4, 
more than one point can be gained from each parameter as long as the description 
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applies.  Once the points have been allocated, they are added up and a score out of 10 
is achieved.  A score of 7 or higher indicates a diagnosis of MD (Gibson, 1990).  This 
point system is considered a helpful clinical tool as it summarises the patient’s 
history, with a quantification scheme giving a clearer direction of a possible 
diagnosis.  However, as the Gibson’s score is obtained based on subjective 
assessment, the information used to obtain the score must be considered carefully or 
this could be a misleading tool if not used properly.  
 
Table 4.   The point system of Gibson’s Score (adapted from Gibson, 1990; p. 109). 
  
  Parameter Description Points 
  
  Vertigo - Rotational vertigo 1 
 - Attacks of rotational vertigo lasting over 10 min 1 
 - Rotational vertigo associated/linked with one or 
    more of:  hearing loss, tinnitus or aural pressure 1 
  Hearing - Sensorineural hearing loss 1 
 - Fluctuating sensorineural hearing loss 1 
 - Hearing loss or fluctuation associated/linked with 
    one or more of:  vertigo, tinnitus or aural pressure 1 
  Tinnitus - Peripheral tinnitus lasting over 5 min 1 
 - Tinnitus fluctuating or changing with one or more  
    of vertigo, hearing loss or aural pressure 1 
  Aural pressure - Constant aural pressure lasting over 5 min 1 
 - Aural pressure fluctuating or changing with one 
    or more of vertigo, hearing loss or tinnitus 1 
  Maximum score  10 
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1.2.3  Electrocochleography 
Electrocochleography is the measurement of an auditory evoked response 
(AER) from the cochlea.  An AER is a response from the auditory system elicited by 
an acoustic stimulus (Hall, 2007).  To elicit an AER, sounds such as clicks and tones 
of varying intensity are played through an acoustic transducer (e.g., a TDH-39 
headphone).  The sound source is positioned into a rubber ring which is placed over 
ear canal entrance, where elastic bands hold the electrode in place resting on the 
auricle.  In most cases, the greater the intensity of the sound, the larger the AER will 
be because the energy ratio between the acoustic signal and environmental noise ratio 
will increase.  The activity of the auditory system in response to the acoustic stimulus 
can be measured at several specific sites on the head with electrodes.  Four electrodes, 
are typically placed on the earlobes, forehead and down the external auditory meatus 
(Hall, 2007).  This corresponds to positions Fp, A1, and A2 respectively according to 
the International 10-20 System of electrode placement (Jasper, 1958).  The differential 
recording is obtained from the electrodes placed on the two linked earlobes (A1 or 
A2) and the electrode down the external auditory meatus.  The other forehead 
electrode (Fp) is the ground electrode.   
The AER responses can also be obtained using other electrophysiological 
techniques for different assessment purposes, such as the auditory brainstem response 
(ABR).  The ABR assesses the auditory pathway at the auditory nerve and brainstem 
structures (Hall, 2007).  The ABR is a useful diagnostic tool for assessment of 
conductive hearing loss, sensorineural hearing loss, and retrocochlear pathology 
(Burkard & Secor, 2002).  The test involves the patient quietly resting while 
electrodes attached to the head measure the brain activity.  The sound stimulation 
through clicks, tone bursts, or chirps delivered to the external auditory meatus 
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normally elicits an AEP in those with a functioning auditory pathway (Hall, 2007).  
This test is used clinically in infants to obtain hearing thresholds and in adults to rule 
out retrocochlear pathology.  As the ECochG method is the instrumental method 
related to the assessment of MD, it is described in detail as follows.  
1.2.3.1  Electrocochleographic Auditory Evoked Responses  
The ECochG waveform represents the amplitude of the AER over time.  The 
AER arises within the first two or three milliseconds after a sudden acoustic stimulus 
is activated.  Originating from the cochlea and the eighth cranial nerve, the normal 
AER consists of three components, the cochlear microphonic (CM), summating 
potential (SP), and the compound action potential (AP).  
The CM signal, which is present throughout the whole duration of an acoustic 
stimulus, is an alternating current (AC) electrical potential.  The CM is predominantly 
generated by the outer hair cells of the cochlea (Patuzzi, Yates & Johnstone, 1989a).  
The CM signal reflects the instantaneous displacement of the basilar membrane in 
response to an acoustic stimulus, reflecting the stimulus waveform (Ferraro, 2000; 
Ferraro & Durrant, 2002; Gibson, 1996).  The displacement of the basilar membrane 
results in the process of mechanoelectrical transduction (MET), which occurs in both 
the outer hair cells and inner hair cells (Yost, 2007).  The CM potential can best be 
described as the extracellular analogue of the AC receptor current, which is carried by 
potassium (Patuzzi, Yates & Johnstone, 1989b).  
Another observable part of the ECochG waveform is the SP, which is the least 
understood cochlear potential.  Both CM and SP are stimulus-induced, generated by 
the hair cells of the cochlea in response to an acoustic stimulus (Ferraro, 2000; Ferraro 
& Durrant, 2002).  However, while the CM reflects the displacement of the basilar 
membrane generated by the activity of the outer hair cells, the SP is considered to be 
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normally generated by the inner hair cells of the cochlea (Ferraro, 2000; Hall, 2007).  
The SP is a direct current (DC) response, and thus representing the stimulus envelope 
(Ferraro, 2000; Hall, 2007).  The SP arises from the asymmetric transfer function of 
the inner hair cells and, as shown in Figure 1, appears as a shift in the baseline from 
CM. 
 
 
Figure 1.  The waveforms (X-axis: time; Y-axis: amplitude) of the combined signals of 
cochlear microphonic (CM) and summating potential (SP) in the top graph, the SP 
waveforms in the middle graph, and the waveform of the acoustic stimulus in the 
bottom graph (adapted from Ferraro & Durrant, 2002; p. 251). 
 
The AP is produced by fibres within the distal (cochlear) portion of the eighth 
cranial (auditory) nerve (Hall, 2007).  The compound AP signal represents a 
collective response resulting from numerous auditory nerve fibres firing 
synchronously (Ferraro & Durrant, 2002).  The AP is usually larger than the SP, with 
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a latency of approximately 1.5 ms (Hall, 2007).  As shown in Figure 2, measurements 
commonly made on the ECochG waveforms are the amplitudes of the SP and AP 
components, using either a peak-to-trough or a baseline reference demarcation method 
(Ferraro, 2000).  
 
 
Figure 2.   A normal ECochG trace using alternating clicks at 80 dB HL.  The amplitudes of 
the SP and AP can be measured by either a peak-to-trough (left graph) or a baseline 
reference (right graph) demarcation method where the SP is subtracted from the AP 
(Ferraro, 2000; p. 435). 
 
It is noteworthy that the CM, along with stimulus artefact, may conceal some 
of the components at the beginning of the ECochG waveforms, making interpretation 
difficult.  To overcome this problem, which may interfere with the differentiation 
between CM and neural response, an alternating polarity stimulus can be employed.  
It has been found that the use of an alternating polarity stimulus will cancel the 
stimulus dependent CM, making the ECochG waveform easier to interpret (Hall, 
2007). 
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1.2.3.2  ECochG Recording Techniques 
There are two common approaches to ECochG recording: transtympanic (TT) 
and extratympanic (ET).  The TT ECochG method involves a recording needle 
electrode being placed down the ear canal and through the tympanic membrane to rest 
on the promontory of the cochlea (Ferraro & Durrant, 2002).  The main advantage of 
this recording technique is the close proximity of the recording needle electrode to the 
cochlea, which enables large ECochG response waveforms to be obtained with a 
minimal signal averaging required (Ferraro & Durrant, 2002;  Ge & Shea, 2002).  
However, there are several limitations to this method.  The TT ECochG method is an 
invasive technique and requires a physician to place the recording needle electrode.  
This can restrict the test to medical settings, and consequently make it an expensive 
test to perform.  In addition, even with local anaesthesia, the penetration of a needle 
through the tympanic membrane can be a painful experience for the patient (Bohlen, 
Arenberg & Gibson, 1990; Ferraro & Durrant, 2002). 
The ET ECochG method is less invasive, with an electrode resting on the 
tympanic membrane or against the skin of the external auditory meatus (Bohlen, 
Arenberg & Gibson, 1990; Ferraro & Durrant, 2002).  The advantage of the ET 
ECochG method is that it is more tolerable for the patient and does not require a 
physician present for the recording (Ferraro & Durrant, 2002).  However, the ET 
ECochG method requires more signal averaging and yields waveforms with a lower 
magnitude than the TT ECochG method, leading to a poorer signal-to-noise ratio and 
thus greater difficulties in the interpretation of the recorded signals (Bohlen, Arenberg 
& Gibson, 1990).   
Bohlen, Arenberg & Gibson (1990) compared the TT ECochG and ET 
ECochG methods by testing a total of 70 ears over a period of 18 months, with each 
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ear’s recordings obtained from both methods on the same day.  Patients were asked to 
rate the comfort of each method during insertion, while the test was conducted, and 
during extraction of the electrode.  The majority of patients (70%) reported no 
difference in the relative comfort between the two methods.  Based on an analysis of 
the recorded signals, the authors reported that the TT ECochG method, as compared 
with the ET ECochG method, yielded a more reliable and reproducible output signal 
and a significantly greater amplitude.  
1.2.3.3  Acoustic Stimulus 
To elicit an ECochG AER, both clicks and tone burst stimuli of varying 
intensity are separately played through an acoustic transducer and the response is 
recorded from an electrode (Gibson, 1991; Hall, 2007).  Each type of stimuli serves a 
different purpose.  Clicks evoke a clear action potential due to their sharp onset but 
can cause acoustic ringing and distort the SP envelop unpredictably.  Tone bursts of 
longer duration enhance the differentiation between SP and AP allowing for accurate 
measurements (Gibson, 1991).  An illustration of the ECochG waveforms in response 
to these two types of acoustic stimuli is shown in Figure 3. 
In a study by Gibson (1993), a 1 kHz tone burst and a click were compared for 
the diagnosis of endolymphatic hydrops, along with his points scoring system for the 
clinical diagnosis of MD (Gibson’s Score).  The TT ECochG method was used to test 
42 normal ears, 48 sensory ears with sensorineural hearing loss, and 80 Ménière’s 
ears.  With the TT ECochG method, the 1 kHz tone burst was found to result in a 
higher accuracy level than the click in detecting MD.  In a later study by Ge and Shea 
(2002), TT ECochG recordings using tone bursts and clicks were made for 2,421 ears 
from May 1990 to April 2000.  It was found that tone bursts had the advantage of 
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frequency selectivity and could show the degree of endolymphatic hydrops at specific 
turns of the cochlea. 
 
 
Figure 3.   Upper trace illustrates an ECochG recording in response to a 2 kHz tone burst 
stimulus in an ear with no endolymphatic hydrops (copied from Ferraro, 2000; p. 
436).  The middle trace illustrates response to a click stimulus and the lower trace 
response to a tone burst stimulus in an ear with endolymphatic hydrops (copied 
from Gibson, 2009; p. 39). 
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1.2.3.4  Endolymphatic Hydrops 
Endolymphatic hydrops is an inner ear pathology that can be identified at post-
mortem.  On examination of the temporal bones, swelling is seen in the 
endolymphatic spaces (Horner, 1993).  This pathology is seen with several clinical 
disorders, including otitis media, meningitis, otosclerosis, trauma, and MD (Paparella, 
1991).  However, endolymphatic hydrops appears to be a consistent feature of MD 
and is thus considered the primary pathology of MD (Horner, 1991). 
Endolymphatic hydrops is thought to change the ECochG waveforms by 
increasing the magnitude of the SP in response to clicks and tone bursts, creating an 
abnormally large potential as illustrated above in Figure 3 (Gibson, Moffat & 
Ramsden, 1977; Gibson, 1996; Conlon & Gibson, 2000).  The effect of 
endolymphatic hydrops on ECochG measures has been demonstrated (Patuzzi, 1996, 
2009).  In a normally functioning inner ear, the inner hair cell (IHC) operating point is 
close to scala tympani (ST) because the hair bundles are velocity coupled.  An 
estimated 10-20% of the mechanoelectrical transduction (MET) channels are open at 
rest in the IHC.  Because the stererocilia of the outer hair cell (OHC) are displacement 
coupled, the OHC operating point is more central, with approximately 40-50% of the 
MET channels being open at rest.  
With endolymphatic hydrops, the displacement of the basilar membrane 
towards ST moves the OHC operating point closer to that of the IHCs.  This results in 
an increase of DC component in the OHC receptor current, adding the OHC SP to the 
IHC SP.  Furthermore, as there are three times as many OHCs as IHCs, the SP 
magnitude increases greatly.  On the other hand, the amplitude of the compound AP is 
decreased.  Most likely this is because of an OHC motor loss, which reduces the 
efficiency of the MET to electromechanical transduction (EMT) active process. 
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Asai and Mori (1989) tested eight patients with MD using ET ECochG and 
reported that the amplitude change of the AP decreased with an increase of hearing 
threshold at high frequencies (2-8 kHz), while at low frequencies (0.25-1 kHz, the 
amplitude of the AP altered independently of the hearing threshold.  However, the SP 
remained constant throughout the fluctuation of hearing loss.  This finding indicates 
that changes of ECochG waveforms are associated with the presence of MD.  An SP-
to-AP ratio in response to a click stimulus with a value greater than 40-50% has been 
shown to indicate the presence of endolymphatic hydrops (Arts, Kileny, & Telian, 
1997).  The amplitudes of the SP and AP (measured in microvolts) have been used to 
determine if a person has normal hearing, sensorineural hearing loss, retrocochlear 
hearing loss, or MD (Hall, 2007).  The ECochG is sensitive to the presence of MD, as 
small changes in the endolymph fluid of the cochlea can affect the ECochG 
waveforms.  As shown in Figure 4, a Ménière’s ear demonstrates a larger SP (whether 
it be positive, as in the high frequencies, or negative, as in the low frequencies) than 
normal ears.  
 
 
Figure 4.   The SP waveforms in response to a 90 dB HL stimulus at different frequencies as 
measured in a normal ear (left graph) and in a Ménière’s ear (right graph) (copied 
from Gibson, 1996; p. 14). 
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1.2.4  Magnetic Resonance Imaging 
Magnetic resonance imaging (MRI) is a neuroimaging tool used to define the 
nature and extent of most disease processes, including those affecting the temporal 
bone and other anatomical structures (Tucci & Gray, 2000).  MRI images have been 
found to be useful for the diagnosis and treatment planning for many diseases (Tucci 
& Gray, 2000).  Imaging of the endolymphatic space clinically has not been achieved 
due to differences in the chemical composition of endolymph in the inner ear 
(Nakashima et al., 2007).  However, in recent years there has been development for an 
appropriate imaging method, and the use of MRI imaging for the diagnosis of MD has 
started to be explored in many hospitals worldwide. 
Nakashima et al. (2007) reported clinical imaging of endolymphatic hydrops 
in nine patients using an intratympanic gadolinium injection.  Each patient was 
injected intratympanically through the tympanic membrane with a needle and an MRI 
scan with a 3 Tesla unit was taken 1 or 2 hours after.  In patients with MD, the 
perilymphatic space was found to be small, indicating the presence of a large 
endolymphatic space in the inner ear.  Several MRI scans of endolymphatic hydrops 
in the vestibule and cochlea have since been reported in patients with inner ear 
diseases.  The MRI imaging of the ear has started in recent years to be used in 
hospitals to standardise the evaluation of endolymphatic hydrops (Nakashima et al., 
2007; Nakashima et al., 2009). 
A recent study at Christchurch Hospital demonstrated imaging of 
endolymphatic hydrops using 1.6 ml in 10 ml saline multihance gadolinium on two 
patients.  One patient had a “definite” MD according to the AAO-HNS CHE criteria 
and a positive ECochG while the other patient had “possible” MD according to the 
AAO-HNS CHE criteria and a negative ECochG.  The patient with “definite” MD 
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also showed hydrops in the imaging, while the other patient did not.  This showed 
complete diagnostic agreement with the AAO-HNS CHE standards and ECochG.   
Having this technology available for future clinical diagnosis is invaluable as 
there is no agreement on a “gold standard” for the diagnosis of MD.  However, this 
method of diagnosis is expensive, and still in the early stages of development.  It 
requires not only a physician to administer the intratympanic gadolinium injection but 
also a radiologist to conduct an MRI imaging procedure.  Most importantly, co-
ordination is needed between the patient, otolaryngologist, and radiologist to ensure 
the procedure works logistically as well as being time efficient.  The MRI imaging 
method is a time consuming test, and requires a 3 Tesla MRI scanner, which is not as 
affordable as other testing equipment.  There is a lack of MRI studies at present in the 
literature, and this method needs to be tested against the current methods of diagnosis 
to create a gold standard if appropriate.  It may be a very powerful tool and change the 
way MD is diagnosed in the future.  Examples of the case study conducted by Dr. 
Jeremy Hornibrook at the Christchurch Hospital are shown in Appendix 1.  
1.2.5  Treatment of MD and the Impact of Diagnosis 
Sajjadi & Paparella (2008) outline several medical and surgical treatments 
offered to patients diagnosed with MD.  Lifestyle changes such as a low salt diet, 
avoidance of tobacco products, caffeine, alcohol and chocolate are often the first step 
for many patients.  Failing this, administration of diuretics or steroids in acute cases 
may be offered or a Meniett device or transtympanic gentamicin.  Failing these 
treatments, surgical intervention may be necessary to relieve patients from their 
symptoms.  Surgery options include endolymphatic sac enhancement, vesticular 
neurectomy or labyrinthectomy. 
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The impact diagnosis has on a patient can be traumatic if incorrect.  Not only 
is the treatment for MD expensive, but it does not utilise resources effectively.  Other 
patients may be on the waiting list longer than necessary, and it is time consuming not 
only for the patient but also for the health professional.  If the wrong treatment is 
given, this may have irreversible effects on the patient, causing great trauma.  It is 
therefore vital that any method used to diagnose MD is accurate.   
It is well established that MD can be very difficult to diagnose correctly, as 
Thorp et al. (2003) demonstrated in a review on MD literature.  Lifestyle changes may 
not directly harm a patient if a misdiagnosis is made; however, administration of 
diuretics, steroids, transtympanic gentamicin, or surgical intervention may have 
serious consequences for the patient if they do not have MD.  Therefore it is 
imperative that a reliable diagnostic tool or tools is agreed on for the diagnosis of MD.  
This may include using the AAO-HNS CHE criteria, ECochG or a combination of 
both and/or with other diagnostic tools such as Gibson’s score or MRI, to ensure 
accurate diagnosis, leading to the appropriate treatment for the patient.   
Challenges with both methods in the diagnosis of MD have occurred, as the 
AAO-HNS CHE is subjective and does not quantify symptoms, while ECochG is 
invasive and requires a physician to administer the test, which may not be available in 
all hospitals.  Treatment is administered once the physician is clinically certain the 
patient has MD, and will vary depending on the practice in the hospital and the 
experience of the attending physician.  Surgery is generally considered a last option to 
eliminate the patient’s symptoms.   
If improvements on the diagnosis of MD can be made treatment can start 
sooner and relieve the patient of their symptoms.  At the present time, the physician 
has to be sure that they have MD before administering any treatment, and this may 
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take several months.  A reliable diagnosis will also save a lot of appointments and 
time with all involved, which is more cost effective.   
1.3  Research Question 
As discussed above, there are several clinical diagnostic tools for MD.  This 
study evaluates the effectiveness of the subjective assessment methods, including 
AAO-HNS CHE criteria (Members of the Committee on Hearing and Equilibrium, 
1995) and Gibson’s score, in comparison to ECochG for detecting MD.   
1.3.1  Rationale and Importance 
As the AAO-HNS CHE criteria approach relies on self-report of the 
symptoms, the classification of the clinical diagnosis remains vague and subjective.   
An objective, instrumental method is needed to improve the diagnosis and 
management of MD.  To date, ECochG has been used by some physicians and 
researchers to assist in the study of MD.  However, the ECochG method has not been 
established as a common diagnostic tool mainly because there remains a lack of 
empirical evidence evaluating its usefulness in clinical diagnosis.  Conlon and Gibson 
(2000) showed in a study of 2,964 ears that ECochG achieved a higher level of 
accuracy in detecting MD than conventional clinical examination.  Empirical evidence 
in support of the effective usage of ECochG will lay foundations to further study for 
increased use of ECochG as a diagnostic tool and to enhance the management of MD.   
1.3.2  Aims and Hypotheses 
The purpose of this study is to gauge the inter-method reliability in the 
detection of MD using measures derived from subjective and instrumental methods.  
Specifically, the main questions are: 
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1. The agreement between diagnostic tools:  How does the method of ECochG 
compare to the AAO-HNS CHE criteria and Gibson’s score in detecting MD?    
2. An evaluation of Electrocochleography: What are the characteristics of the 
patients tested “positive” with the ECochG measures as compared with those 
classified by the other two subjective measures? 
Based on clinical observations and the findings reported in the literature, it 
was hypothesized that ECochG would yield more defined results in the diagnosis of 
MD than the conventional AAO-HNS CHE criteria.  The rationale for this hypothesis 
is that ECochG is more defined as it objectively yields a positive or negative testing 
result to confirm diagnosis while the AAO-HNS CHE criteria only gives broader 
definitions as to whether a person has MD or not.  It is hypothesized that a 
comparison between patients tested “positive” with the ECochG measures and those 
tested “negative” would reveal differences in the relationship between various 
experimental measures due to different patterns of variability related to differences in 
the underlying pathophysiology.  
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Chapter Two:  Methodology 
_____________________________________________________________________  
 
2.1  Participants and Participants’ Task 
Medical records were retrieved to obtain data retrospectively using a quota 
sampling method.  Subjects included a total of 250 patients (117 females and 133 
males) who had been referred to the department of Otolaryngology at the 
Christchurch Hospital (Christchurch, New Zealand) in the period from 1994 to 2009.  
All subjects included had complete records of the patient’s hearing test, clinical 
examination, evaluations performed using AAO-HNS CHE criteria, Gibson’s score, 
and ECochG testing and results from the diagnosis of MD.  The age of the patients 
ranged from 9 and 88 years of age (Mean = 53 years, SD = 14.42).   
Before assessment by an otolaryngologist, an audiologist completed a 
diagnostic air conduction pure tone audiogram using the modified Hughson-Westlake 
procedure to detect the thresholds for 250, 500, 1,000, 2000, 4,000 and 8000 Hz for 
each subject bilaterally.  The bone conduction threshold was obtained at the 
frequencies where the air conduction threshold was greater than 20 dB HL to 
determine whether a conductive or sensorineural hearing loss was present.  The 
otolaryngologist took a detailed history of the patient and performed otoscopy, tuning 
fork tests such as the Weber and Rinne tests and a vestibular exam consisting of the 
Romberg test, Unterberger Stepping Test, Head-thrust test, Hallpike test, and other 
tests which examine cranial nerve function, cerebellum, eye movements, and the 
presence of nystagmus.  
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Patients referred for a MD examination were put on a waiting list for ECochG 
testing, which was approximately two months after the initial clinical examination 
with the otolaryngologist.  Patients were also advised to avoid excessive salt in their 
diet, and if appropriate, given Betahistine or other medication to help alleviate 
symptoms.  Once a hearing test and ECochG results were obtained, the patient was re-
evaluated for any further medical intervention.  The patient was then reviewed in 6 
months or a year if no further problems occurred.  
2.2  Instrumentation 
Instruments used for the recording of ECochG signals included an 
electrodiagnostic system (Amplaid MK 15, Milan, Italy), disposable electrodes 
(Ambu Blue Sensor electrodes, Denmark), a sterilised transtympanic needle electrode, 
phenol, elastic bands, and a supra-aural headphone positioned on a ring.  The 
instrument used for data entry included laptop equipped with a relationship database 
program (Microsoft Access 2002).  The instrumental setup is shown in Figure 5.  
Calibration of the electrodiagnostic system was completed annually in August 
by ECS Ltd, New Zealand.  The machine was connected to the patient via a series of 
connections.  Electrodes were placed on the patient (active transtympanic needle 
electrode on promontory, an indifferent electrode on each earlobe, and ground 
electrode on the forehead).  The four electrodes were then connected through wires to 
a biological amplifier, which was connected to the electrodiagnostic system via a long 
cable.  From the electrodiagnostic system, the headphones were attached via a long 
cable to the patients head. 
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2.3  Procedure 
The ECochG recording was conducted in the department of Otolaryngology at 
the Christchurch Hospital (Christchurch, New Zealand).  The skin was prepared with 
Medi-Swab alcohol skin cleansing swabs (BSN Medical) and then the ground 
electrode was placed on the forehead and the two indifferent electrodes were placed 
on each earlobe.  The tympanic membrane was anaesthetised with a drop of phenol 
before the insertion of the active electrode needle, which was a sterilised 
transtympanic needle electrode piercing through the tympanic membrane to rest on 
the promontory of the cochlea.  Elastic bands attached to a ring 6.5 cm in diameter, 
(similar to a supra-aural headphone) were positioned over the auricle (pinna) of the 
test ear to secure the needle in place.  The patient was instructed to lie in a supine 
position during testing to decrease muscle noise while the recording took place.  A 
headphone sound source was located on the ring over the test ear and air conduction 
tone burst and click stimuli were used to extract an ECochG response.  
The tone burst stimuli used to elicit ECochG AER were set at the frequency of 
0.5, 1, 2, and 4 kHz respectively.  The intensity of the tone bursts were 90 dBnHL for 
the frequencies at 500, 1,000, and 2,000 Hz, and 100 dBnHL at 4,000 Hz.  The rise 
and fall time specified for the tone burst was 1 ms with a 14 ms plateau, with a total 
duration of 16 ms.  The click stimuli were presented at an intensity of 90 dBnHL with 
a duration of 100 µs and alternating polarity at a rate of 10 times per second.  A total 
of 1,024 stimulus presentations per run were delivered for the tone burst stimuli and 
recorded, along with the response signals, with an analysis time window of 30 ms.  A 
total of 256 stimulus presentations per run were delivered for the click stimuli and 
recorded, along with the response signals, with an analysis time window of 10 ms.  
Both the acoustic stimuli and the AER signals were filtered respectively through a 
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band-pass filter, which consisted a low-pass filter at 3 kHz with a 12 dB per octave 
filter slope and a high-pass filter at 0.5 Hz with a 6 dB per octave filter slope.  
2.4  Measurements 
Experimental measures in this study were derived from pure tone audiometry, 
Gibson’s score, AAO-HNS CHE, and electrocochleography test results.  
2.4.1  Pure Tone Audiometry Measurements 
Data retrieved from the medical records regarding the results of the pure tone 
air conduction audiogram were hearing thresholds measured at five frequencies:  500, 
1,000, 2,000, 4,000, and 8,000 Hz.  Each patient may have more than one documented 
audiogram in the medical record because the patient might have had several hearing 
tests over the course of undergoing evaluation and treatment at the Christchurch 
Hospital.  A mean threshold called a pure tone average (PTA) was calculated for each 
ear tested on the same day by averaging the thresholds measured at 500, 1,000, and 
2000 Hz for each ear.  
2.4.2  AAO-HAS CHE Measurements 
The AAO-HNS CHE criteria as shown above in Table 3 were noted by an 
otolaryngologist for each patient.  Any unique details of the patient’s history were 
also noted along with the type of hearing loss and presence of vertigo attacks, tinnitus, 
aural fullness, disequilibrium and other causes excluded.  
2.4.3  Gibson’s Score Measurements 
A Gibson’s score was calculated by an otolaryngologist for each patient on 
each visit.  The scoring was based on the standard point system as shown in Table 4.  
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2.4.4  Electrocochleography Measurements 
Measurements from the ECochG signals recorded for each patient included 
measures derived from signals in response to two types of acoustic stimuli, namely, 
tone bursts and clicks.  Tone burst measurements included the summating potential 
amplitude (measured in µV), which were then compared against the 
electrocochleography norms as shown below in Table 5 (Gibson, 1994), along with 
action potential amplitude (in µV) and a SP-to-AP ratio, which was an amplitude ratio 
between the summing potential and action potential ratio.  These were documented for 
each ear at 0.5, 1, 2, and 4 kHz.  Similarly, click measurements included the 
summating potential amplitude (in µV), action potential amplitude (in µV), and a SP-
to-AP ratio (in %).   
2.5  Data Analysis 
The required data was extracted from each medical record and entered into a 
Microsoft Access database.  Data entered into the database included the patient’s 
basic demographic information, including name, date of birth, sex, and identity 
number.  In addition, the specific test results for auditory thresholds, Gibson’s score, 
ECochG measurement, and components related to the AAO-HNS CHE criteria were 
obtained for each patient.   
The AAOHNS CHE outcome was analysed with regard to the symptoms 
indicated on the patient’s medical records.  The criteria set by the Members of the 
Committee on Hearing and Equilibrium (1995) as previously described were used to 
determine whether a patient would be classified as having “possible”, “probable”, 
“definite”, or “certain” MD.  Each Gibson’s Score was obtained based on the scores 
recorded for the components included in the points system (Gibson, 2009).    
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Table 5.   Electrocochleography norms (adapted from Gibson, 1994). 
 
Clicks: Abnormal if SP/AP ratio > 0.50 
Tone Bursts: 
  
  Tone Burst Frequency Hearing Level DBHL Abnormal if SP < 
  
  500 Hz (75 DBHL) under 25 -2 µV 
 20 - 35 -2 µV 
 40 - 55 -2 µV 
 60 - 75  -1 µV 
  1 kHz (90 DBHL) under 25 -6 µV 
 20 - 35 -6 µV 
 40 - 55 -6 µV 
 60 - 75  -3 µV 
  2 kHz (100 DBHL) under 25 -9 µV 
 20 - 35 -7 µV 
 40 - 55 -5 µV 
 60 - 75  -5 µV 
  4 kHz (75 DBHL) under 25 -9 µV 
 20 - 35 -5 µV 
 40 - 55 -5 µV 
 60 - 75  -5 µV 
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2.6  Statistical Analysis 
Measures yielded by the three diagnostic tools, including ECochG, AAO-HNS 
CHE, and Gibson’s score, were compared.  Based on the ECochG measures, patients 
with any recorded SP values for clicks or tone bursts greater than the normative data 
values, as specified in Table 5, were classified as “positive” and those with none of 
the recorded SP values greater than the normative data values were classified as 
“negative”.  With the ECochG diagnostic test as the hypothetical “gold standard”, the 
sensitivity and specificity of the two subjective tests, including AAO-HNS CHE 
criteria and Gibson’s score, were calculated based on the formula as shown in Table 
6.  An ROC curve was plotted for both subjective tests to derive the proportion of 
patients who were correctly identified as having MD on the Y-axis against the 
proportion of patients who were incorrectly identified as having MD on the X-axis.  
The best cut-off point for each of the two ROC curves was chosen for assessment of 
inter-method reliability.  To determine the level of agreement between the three 
diagnostic tools, four types of inter-method reliability, including total, point-by-point, 
occurrence, and non-occurrence reliability, were also calculated based on the formula 
as shown in Table 7.  With “positive” and “negative” identifications made through the 
three diagnostic tools respectively, a series of chi-square tests were conducted to 
compare the number of patients in groups related to different classifications.  A series 
of correlation procedures were also conducted to determine the relationships between 
a selection of experimental measures as a whole or in the “positive” and “negative” 
groups respectively.  The significance level was set at 0.1, with adjustments using the 
Bonferroni correction in multiple testing. 
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Table 6.   Formula for calculating the diagnostic power of the two subjective tests 
respectively as compared with ECochG diagnosis. 
 
 
      
    ECochG diagnosis 
   (Hypothetical “gold standard”)  
 
        Positive Aegative  
 
 
Positive 
a 
(true positive) 
 
b 
(false positive) 
          Results from    
     AAO-HAS CHE 
  (or  Gibson’s Score)  
 
Aegative 
 
c 
(false negative) 
 
 
d 
(true negative) 
 
 
 Sensitivity = a/(a+c) 
 Specificity = d/(b+d) 
 Positive predictive value = a/(a+b) 
 Negative predictive value = d/(c+d) 
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Table 7.   Conditions given for the calculation of four types of inter-method reliability  
 
[formula:  Reliability = (a/b) X 100]. 
  
 Type of reliability Conditions 
  
 
Total reliability  a = the smaller frequency of “positive” identification by one test 
 b = the larger frequency of “positive” identification by the other test 
 
 
Point-by-point  a = the number of cases with the same identification from both tests 
reliability b = the total number of cases 
  
 
Occurrence  a = the number of cases tested “positive” in both tests 
reliability b = the number of cases tested “positive” at least in one test 
  
 
Non-occurrence  a = the number of cases tested “negative” in both tests 
reliability b = the number of cases tested “negative” at least in one test 
  
  
 
2.7  Ethical Considerations 
Ethical approval was obtained from the Upper South A Regional Ethics 
Committee from the New Zealand Ministry of Health, Health and Disability Ethics 
Committees (Ref: URA/09/06/EXP) on 4 March 2009 and the University of 
Canterbury Human Ethics Committee (Ref: HEC 2009/LR/10) on 2 April 2009 
(Appendix 2). Patients who were tested for MD were approached by the 
Otolaryngologist at the time of testing and gave verbal consent to participate in MD 
research.  Patient confidentiality was maintained in accordance with the above named 
ethics committees. 
  38 
Chapter Three:  Results 
_____________________________________________________________________  
 
This chapter presents results from analysis of the agreement among three 
diagnostic tools in the detection of MD and a series of comparisons between 
“positive” and “negative” cases as classified with different diagnostic tools. 
3.1  Agreement between Diagnostic Tools  
Results on the agreement between ECochG and AAO-HNS CHE criteria, 
between ECochG and Gibson’s Score, and between Gibson’s score and AAO-HNS 
CHE criteria were reported separately as follows. 
3.1.1  ROC Curves for AAO-HAS CHE Criteria and Gibson’s Score 
The ROC curves for the two subjective tests as compared with the ECochG 
diagnosis were plotted in Figure 6, with three cut-off points (“possible”, “probable”, 
and “definite”) for the AAO-HNS CHE criteria and eleven cut-off points (from 0 to 
10 in steps of one) for the Gibson’s score test.  The area under the curve for the 
Gibson’s score test was significantly greater than that for the AAO-HNS CHE test 
(Chi-square = 22.51, df =1, p < 0.001), indicating that Gibson’s score test was more 
powerful in discriminating between “positive” and “negative” ECochG cases.  The 
ROC curve for the Gibson’s score test appears to turn at the cut-off point of seven, 
which falls on the cut-off value recommended by Gibson (1994) to make a positive 
MD diagnosis.  The shape of the ROC curve for the Gibson’s score plotted with the 
ECochG diagnosis as the hypothetical “gold standard” is typical of a ROC curve 
constructed when a real “gold standard” diagnosis is available for comparison, 
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indicating that ECochG testing provides a valid alternative to the two subjective 
methods.   
 
1 - Specificity
(False positives)
0.0 0.2 0.4 0.6 0.8 1.0
Sensitivity
(True positives)
0.0
0.2
0.4
0.6
0.8
1.0
Gibson's score, Area = 0.79
AAO-HNS CHE, Area = 0.66
"Definite"
"Probable"
"Possible"
GS >= 6
GS >= 7
 
Figure 6.   A receiver operating characteristic (ROC) curve showing the relationship between 
sensitivity and 1-specificity of the Gibson’s score test at 11 cut-off points (right to 
left from 0 to 10) and that of the AAO-HNS CHE test at 3 cut-off points 
(“possible”, “probable”, and “definite”).   
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Figure 7 shows the percentage of patients in the “positive” and “negative” 
groups as classified with different diagnostic methods.  The ECochG diagnosis was 
based on the classification scheme as described in the previous chapter.  The AAO-
HNS CHE criteria were changed to a dichotomous classification in two ways.  One is 
to group “Definite” and “Probable” as “positive” (“AAO-Definite/Probable”) and the 
other is to label only “Definite” as “positive” (“AAO-Definite”).  The Gibson’s score 
with a cut-off point of 7 was used for making the diagnosis.  As shown in Figure 7, 
both ECochG measures and AAO-HNS CHE criteria identified more positive cases 
(“ECochG”: 144; “AAO-Definite”: 144; “AAO-Definite/Probable”: 154; “Gibson’s 
Score”: 115) than negative cases while the approach with Gibson’s score identified 
more negative cases than positive cases.    
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Figure 7.   Percentage of patients identified as “positive” and “negative” respectively using 
different diagnostic methods, including ECochG, AAO-HNS CHE criteria with 
only “Definite” as “positive” (AAO-Definite), AAO-HNS CHE criteria with both 
“Definite” and “Probable” as “positive” (AAO-Definite/Probable), and Gibson’s 
score with the cut-off point at a value of 7. 
 
3.1.2  Inter-method Reliability 
Results of a series of inter-method reliability test conducted between ECochG 
and AAO-HNS CHE criteria, ECochG and Gibson’s score, and AAO-HNS CHE 
criteria and Gibson’s score were illustrated in Figure 8.  The point-by-point, 
occurrence, and non-occurrence reliability were highest between the AAO-HNS CHE 
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criteria and Gibson’s score, while the total reliability was highest between the 
ECochG method and AAO-HNS CHE criteria.  
Type of Reliability
Total Point-by-Point Occurrence Non-Occurrence
Reliability
(in %)
0
20
40
60
80
100
120
ECochG-AAO 
ECochG-Gibson 
AAO-Gibson 
 
Figure 8.   Total, point-by-point, occurrence and non-occurrence reliability between ECochG 
measures and AAO-HNS CHE criteria, between ECochG measures and Gibson’s 
score, and between AAO-HNS CHE criteria and Gibson’s score. 
 
3.1.2.1  ECochG and AAO-HS CHE Criteria 
With the “AAO-Definite” method, the degree of agreement between AAO-
HNS CHE and ECochG diagnosis was evaluated.  As shown in Figure 8, the total 
reliability between ECochG and AAO-HNS CHE criteria was relatively high but the 
point-by-point reliability was only moderately high.  The occurrence reliability was 
slightly more than 10% higher than the non-occurrence reliability, indicating that the 
  43 
inter-method agreement between ECochG and AAO-Definite methods was higher in 
identifying positive cases than in identifying negative cases.  Specifically, 28.4% 
(41/144) patients tested “positive” with the ECochG measures were missed by the 
AAO-HNS CHE criteria, labelling them as only “possible” (37 patients) or “probable” 
(4 patients), while a higher proportion of “negative” ECochG cases, 38.7% (41/106), 
was considered “positive” based on the AAO-HNS CHE criteria.   
The distributions of positive and negative ECochG cases across the three 
AAO-HNS CHE categories (“possible”, “probable”, and “definite”) respectively are 
shown in Figure 9.  Both “positive” and “negative” ECochG cases were found in all 
of the three AAO-HNS CHE categories of diagnosis.  However, as shown in Figure 9, 
a general agreement existed between the two diagnostic tests, with a relatively high 
proportion (over 70%) of “positive” ECochG cases found in the “definite” category 
and a moderately high proportion (over 50%) of “negative” ECochG cases found in 
the “possible” category.   
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Figure 9.   The respective distribution of “positive” and “negative” ECochG cases across the 
three categories of AAO-HNS CHE criteria. 
 
3.1.2.2  ECochG and Gibson’s Score 
According to the Gibson’s scale, a patient was considered “positive” for the 
diagnosis of MD when achieving a Gibson’s score of seven or greater and “negative” 
if less than seven.  As shown in Figure 8, the total and point-by-point reliability 
between ECochG and Gibson’s score was both high, with the occurrence reliability 
only very slightly better than the non-occurrence reliability.  The distributions of 
positive and negative ECochG cases across the eleven levels of Gibson’s score 
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respectively are shown in Figure 10.  It can be observed from Figure 10 that the  
distribution of “negative” ECochG cases (frequency shown as grey bars) gravitated to 
the lower end of the Gibson scale and the distribution of the “positive” ECochG cases 
(black bars) gravitated to the higher end of the scale. Specifically, a higher proportion 
of positive ECochG cases were found in a Gibson’s score around 6 and 7 and above.  
A higher proportion of negative ECochG cases were associated with a Gibson’s score 
below 6, with a dramatic decrease of negative ECochG cases at a Gibson’s score of 7.   
Gibson Score
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Patients
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15
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Figure 10.   The respective distribution of “positive” and “negative” ECochG cases   across 
different levels of Gibson’s score. 
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3.1.2.3  Gibson’s Score and AAO-HS CHE Criteria 
With the cut-off points for MD diagnosis with both Gibson’s score and AAO-
HNS CHE as previously described, Gibson’s score and AAO-HNS CHE generally 
showed a relatively high inter-method reliability (see Figure 8).   The distributions of 
positive and negative AAO-HNS cases across the eleven levels of Gibson’s score 
respectively are shown in Figure 11.  In a similar manner as previously described 
regarding the cross-over of the distributions of “positive” and “negative” ECochG 
cases on the Gibson’s scale, the direction of the frequency difference between 
Gibson’s score and AAO-HNS CHE test was reversed around a Gibson’s score of 7.  
Gibson Score
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Figure 11.   The respective distribution of “positive” and “negative” AAO-HNS CHE cases 
across different levels of Gibson’s score. 
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3.1.2.4  Tone-burst and Click ECochG 
A comparison of tone-burst and click ECochG results for the total number of 
patients diagnosed with a positive ECochG is shown in Figure 12.  There were 
numerous positive tone-burst ECochG results compared to positive click ECochG 
results.  In particular, the 1 and 2 kHz tone-burst ECochG measures yielded more 
positive outcomes than 500 Hz and 4 kHz.  Table 8 shows the correlations between 
the SP/AP ratios obtained from click ECochG and tone-burst ECochG at 0.5, 1, 2, and 
4 kHz from the same ear.  As shown in Table 8, these correlations were generally low 
except for the correlation between click and the tone-burst ECochG at 2 kHz, where 
the a stronger correlation was found in “positive” group than in the “negative” group.  
 
Figure 12. Number of “positive” tone burst and click ECochG results. 
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Table 8.   Correlations (Pearson’s r) between SP/AP ratios obtained from click 
ECochG and those from tone-burst ECochG at 500, 1,000, 2000, and 
4,000 Hz in the “positive” (POS) and “negative” (NEG) cases classified 
by three diagnostic methods.   
  
 EcochG AAO-Definite Gibson  
       
 POS NEG POS NEG POS NEG 
  
    500 Hz R 0.17 0.01  0.23 0.07 0.23 0.08 
  L 0.08 -0.02  0.22 0.01 0.14 0.16 
 
  
 1,000 Hz R 0.39 0.20 0.45 0.38 0.47 0.35 
  L 0.35 0.19  0.45 0.35 0.41 0.39 
 
   
 2000 Hz R 0.47 0.23 0.55* 0.35 0.57* 0.34 
  L 0.36 -0.03 0.47 0.21 0.47 0.23 
 
 4,000 Hz 
  R 0.27 0.21 0.39 0.18 0.31 0.29 
  L 0.12 0.08 0.21 0.13 0.19 0.15  
  
*  Significant correlations with a coefficient above 0.5 are in boldface. 
 
3.2  Comparisons between “Positive” and “Aegative” ECochG Cases 
Results from an analysis of the distributions of “positive” and “negative” 
ECochG cases across symptoms, types of hearing loss, and various classifications 
were shown as follows. 
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3.2.1  Relationships between Symptoms of MD 
Figure 13 shows the percentage of patients exhibiting each of the four key MD 
symptoms, including hearing loss, vertigo, tinnitus, and feeling of aural fullness.  In 
general, there were a higher proportion of patients exhibiting each of these symptoms 
in the group tested “positive” with ECochG measures than the “negative” group.  
Both hearing loss and vertigo were highly prevalent in the patients included in this 
study regardless of ECochG diagnosis.  As shown in Figure 13, for patients that tested 
“positive” with ECochG measures, hearing loss was the most prevalent symptom, 
followed in order by vertigo, tinnitus, and feeling of aural fullness.  For patients tested 
“negative” with ECochG measures, vertigo was the most prevalent symptom, 
followed in order by hearing loss, tinnitus, and feeling of aural fullness.  With the 
significance level adjusted from 0.1 to 0.016 for multiple testing, no significant 
difference on the occurrence rate was found between hearing loss and vertigo 
(“positive” ECochG: Chi-square = 0.098, df = 1, p = 0.75; “negative” ECochG: Chi-
square = 0.615, df = 1, p = 0.43).  A significant difference on occurrence rate was 
found for all the other pair-wise comparisons, including those between hearing loss 
and tinnitus (“positive” ECochG: Chi-square = 44.5, df = 1, p < 0.001; “negative” 
ECochG: Chi-square = 8.621, df = 1, p = 0.003), hearing loss and aural fullness 
(“positive” ECochG: Chi-square = 74.37, df = 1, p < 0.001 ; “negative” ECochG: Chi-
square = 51.65, df = 1, p < 0.001), vertigo and tinnitus (“positive” ECochG: Chi-
square = 7.645, df = 1, p = 0.006; “negative” ECochG:  Chi-square = 14.73, df = 1, p 
< 0.001), vertigo and feeling of aural pressure (“positive” ECochG: Chi-square = 
23.69, df = 1, p < 0.001 ; “negative” ECochG:  Chi-square = 63.88, df = 1, p < 0.001), 
and tinnitus and feeling of aural pressure (“positive” ECochG:  Chi-square = 6.07, df 
= 1, p = 0.014; “negative” ECochG: Chi-square = 18.79, df = 1, p < 0.001).   
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Figure 13.   Percentage of patients showing each of the four key symptoms of MD. 
 
Table 9 provides a summary of the results from a series of Spearman’s rho 
correlation procedures conducted between the Gibson’s sub-scores for the four key 
symptoms of MD, including hearing loss, vertigo, tinnitus, and feeling of aural 
fullness.  Regardless of the method used for MD diagnosis, “positive” diagnosis was 
generally associated with a high correlation among the four key symptoms while 
“negative” diagnosis showed relatively marginal or no significant correlations 
between symptoms.   
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Table 9.   Correlations (Spearman rho) between the four key symptoms in the “positive” 
(POS) and “negative” (NEG) cases classified by three diagnostic methods.   
  
 Hearing Loss Vertigo Tinnitus  
       
 POS NEG POS NEG POS NEG 
  
ECochG: 
 
 Vertigo R 0.77* 0.21 
  L 0.79* 0.17 
   
 Tinnitus R 0.67* 0.18 0.57* 0.44 
  L 0.71* 0.33 0.70* 0.33 
 
 Aural fullness 
  R 0.53* 0.42 0.51* 0.46 0.58* 0.44 
  L 0.59* 0.02 0.53* 0.17 0.57* 0.20 
 
AAO-HS CHE (“Definite” as positive): 
 
 Vertigo R 0.80 0.17 
  L 0.80 0.16 
   
 Tinnitus R 0.66 0.18 0.75* -0.07 
  L 0.70 0.17 0.73* 0.005 
 
 Aural fullness 
  R 0.58 0.28 0.64* -0.01 0.52* 0.45 
  L 0.53 0.17 0.56* 0.03 0.44 0.41 
 
Gibson’s Score (cut-off point at 7): 
 
 Vertigo R 0.92* 0.08 
  L 0.89* 0.21 
   
 Tinnitus R 0.73* 0.05 0.81* -0.06 
  L 0.80* 0.23 0.87* 0.19 
 
 Aural fullness 
  R 0.57* 0.22 0.61* 0.03 0.50* 0.40 
  L 0.61* 0.01 0.67* -0.02 0.62* 0.08 
  
*  Significant correlations with a coefficient above 0.5 are in boldface. 
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3.2.2  Hearing Loss Patterns 
 Results of an analysis of the distributions of “positive” and “negative” 
ECochG cases across different levels of hearing loss are illustrated in Figure 14.  It 
could be observed from Figure 14 that the mode of the “negative” ECochG cases 
tended to lean toward the end of normal hearing while the “positive” ECochG cases 
mostly presented with a mild to moderate-to-severe hearing loss.  Figure 15 illustrates 
the between-ear contrast on hearing threshold.  There were generally a higher 
proportion of asymmetrical hearing thresholds, with similar occurrence rate for the 
left or right ear to be the poorer ear.  However, the “positive” ECochG group was 
found to have a significantly higher proportion of patients showing asymmetrical 
hearing thresholds than the “negative” ECochG group (Chi-square = 9.66, df =1, p = 
0.002).  In addition, the occurrence rate across the three types of between-ear contrast 
was found to be significantly different in the “positive” ECochG group (Chi-square = 
46.15, df = 2, p < 0.001) but not in the “negative” ECochG group (Chi-square = 2.51, 
df =2, p = 0.286).  As shown in Figure 15, the occurrence rates for the left or right ear 
to be the poorer ear were not significantly different (Chi-square = 0.058, df = 1, p = 
0.811) but there was, in the “positive” ECochG group, a significantly lower 
occurrence rate of symmetrical threshold as compared with asymmetrical threshold 
shift, whether the poorer threshold was found in the left ear (Chi-square = 34.59, df = 
1, p < 0.001) or right ear (Chi-square = 38.548, df = 1, p < 0.001). 
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Figure 14.   The respective distribution of “positive” and “negative” ECochG cases across 
different levels of hearing loss. 
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Figure 15.   The respective distribution of “positive” and “negative” ECochG cases across three 
types of between-ear contrast on hearing loss.  Significantly different between-type 
comparisons were marked with different letters.  Significantly different between-
diagnosis comparisons were marked with an asterisk (“*”). 
 
As for the level of between-ear threshold difference, Figure 16 illustrates a 
comparison between the “positive” and “negative” ECochG groups on the proportions 
of patients with low (0-15 dB HL) and high (equal or greater than 20 dB HL) 
between-ear threshold differences.  As shown in Figure 16, a significantly higher 
proportion of “positive” cases exhibited greater between-ear threshold difference 
(Chi-square = 11.12, df = 1, p < 0.001) while a significantly higher proportion of 
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“negative” cases showed lower between-ear threshold difference (Chi-square = 84.84, 
df = 1, p < 0.001).    
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Figure 16.   The respective distribution of “positive” and “negative” ECochG cases across two 
different levels of between-ear threshold differences.  
 
Figure 17 shows the average hearing thresholds at 0.5, 1, 2, and 4 kHz for the 
“positive” and “negative” ECochG groups respectively.  It can be observed from 
Figure 17 that the “negative” ECochG groups have a lower average hearing threshold 
at all frequencies than the “positive” ECochG groups.  The highest hearing threshold 
is at 4 kHz for both “positive” and “negative” ECochG groups.     
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Figure 17.   Means and standard deviations of the hearing thresholds as measured at 0.5, 1, 2, 
and 4 kHz  frequencies for the “positive” and “negative” ECochG groups. 
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3.2.3  Relationships between ECochG Measures   
Table 10 shows the results from a series of Pearson’s Product Moment 
correlation procedures conducted to determine the relationships between the SP/AP 
ratios obtained at 0.5, 1, 2, and 4 kHz respectively in the “positive” and “negative” 
groups as classified by the three diagnostic tools respectively.  As shown in Table 10, 
the SP/AP ratios measured at adjacent frequencies (i.e., 0.5 and 1 kHz, 1 and 2 kHz, 
and 2 and 4 kHz) were positively and moderately or highly correlated in the 
“positive” group regardless of the type of diagnostic tool used.  This correlation may 
or may not be maintained in the “negative” group, especially for the correlation 
between the 2 and 4 kHz in the “negative” ECochG group.   
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Table 10.   Correlations (Pearson’s r) between SP/AP ratios obtained at 0.5, 1, 2, and 4 kHz 
in the “positive” (POS) and “negative” (NEG) cases classified by three diagnostic 
methods.   
  
 
 500 Hz 1,000 Hz 2000 Hz  
       
 
 POS NEG POS NEG POS NEG 
  
ECochG: 
 
 1,000 Hz R 0.49 0.20 
  L 0.52 0.44 
   
 2000 Hz R 0.37 0.22 0.70 0.63 
  L 0.37 0.38 0.72 0.47 
 
 4,000 Hz 
  R 0.26 0.19 0.42 0.21 0.48 0.31 
  L 0.22 0.23 0.35 0.51 0.53 0.34 
 
AAO-HS CHE (“Possible” as negative): 
 
 1,000 Hz R 0.50 0.43 
  L 0.61 0.50 
   
 2000 Hz R 0.42 0.36 0.74 0.75 
  L 0.45 0.51 0.71 0.69 
 
 4,000 Hz 
  R 0.39 0.17 0.43 0.48 0.46 0.57 
  L 0.21 0.41 0.29 0.65 0.52 0.47 
 
Gibson’s Score (cut-off point at 7): 
 
 1,000 Hz R 0.51 0.41 
  L 0.60 0.51 
   
 2000 Hz R 0.46 0.31 0.78 0.70 
  L 0.41 0.50 0.70 0.69 
 
 4,000 Hz 
  R 0.42 0.16 0.43 0.46 0.47 0.54 
  L 0.17 0.43 0.22 0.64 0.44 0.55 
  
*  Significant correlations with a coefficient above 0.5 were in boldface. 
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The finding of a higher correlation between ECochG measures in the 
“positive” group than the “negative” group suggested that the consistency of SP/AP 
ratios across frequencies may be a sign of MD.  Therefore, the coefficient of variation 
(COV) of the mean and standard deviation of the SP/AP ratios extracted from the four 
frequencies was obtained for each ear.  The COV was defined as 100 times the ratio 
of standard deviation to mean.  The value from the ear with a higher COV was 
selected for each patient for statistical analysis.  Figure 18 shows the means and 
standard deviations of the COV in the “positive” and “negative” groups as classified 
by the three diagnostic methods (ECochG, AAO-Definite, Gibson’s Score with the 
cut-off point at 7).  The six sets (2 diagnostic groups X 3 diagnostic methods) of COV 
values were submitted to a two-way Analysis of Variance.  Results revealed no 
significant method effect [F(2, 76) = 0.236, p = 0.79] but a significant diagnostic 
group effect [F(1, 726) = 26.244, p < 0.001] and method by group interaction effect 
[F(2, 726) = 5.063, p = 0.007].  As shown in Figure 18, the “positive” group had a 
higher mean COV than the “negative” group regardless of the method used for the 
classification.  Post-hoc testing revealed that the COV in the “positive” group was 
significantly higher than that in the “negative” groups only when the classification 
was based on ECochG measures.  As eleven patients in this sample had ECochG 
recordings at other times, the change of COV over time for patients with repeated 
ECochG recordings at different points of time was shown in Appendix 3.  For these 
patients, the ECochG measures recorded at the last day on the record had been 
selected for use in all analysis in the previous section. 
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Figure 18.   Means and standard deviations of the coefficient of variation (for tone burst 
ECochG across frequencies) obtained from the “positive” and “negative” patients 
as classified by three diagnostic methods, including ECochG, AAO-HNS CHE 
criteria with only “Definite” as “positive”, and Gibson’s score with the cut-off point 
at a value of 7. 
 
3.2.4  Demographic Information 
An analysis of the demographic data revealed that more males were diagnosed 
with MD than females in this study (see Figure 19).  The majority of the subjects in 
this particular sample were European, with only a few patients from other ethnic 
groups (See Figure 20).  The majority of the patients (87.24%) who tested “positive” 
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for MD with ECochG measures were between the ages of 41 and 80 years of age (see 
Figure 21).  It was shown in Figure 22 that more “positive” ECochG cases had 
unilateral rather than bilateral MD.  Furthermore, more bilateral MD cases were 
identified using the ECochG method as compared with the Gibson’s score (See Figure 
23).  Figure 24 showed the total number of ears tested as shown in the Gibson scale 
from the AAO-HNS CHE diagnosis.  It could be observed that a “positive” AAO-
HNS CHE criteria diagnosis can be made throughout Gibson’s scale, not just above 
the cut-off score of 7.  This occurs in particular, at the Gibson score of 2 and 3.  
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Figure 19.   Percentage of “positive” ECochG cases in each gender. 
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Asian: 6 
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Figure 20.   Ethnicity of all the 250 patients included in this study. 
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Figure 21.   Percentage of “positive” ECochG cases in each age range as compared to the AAO-
HNS CHE diagnosis. 
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Figure 22.   Percentage of “positive” ECochG cases presenting with a unilateral left or right ear 
or bilateral sign of MD. 
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Figure 23.   The number of patients identified as having bilateral Ménière’s disease. 
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Figure 24.   Total number of ears tested as shown in the Gibson scale from the AAO-HNS CHE 
diagnosis. 
 
3.3  Summary of Main Findings 
The ROC curves showing the relationship between the two subjective 
assessment tools when compared against the ECochG diagnosis had a shape 
characteristic of an ROC curve generated with a “gold standard” for comparison.  The 
agreement between the three tests was generally high, with a few disagreements on 
individual diagnoses.  The ECochG method was found to identify more patients with 
bilateral MD than the Gibson’s score.  Patients who tested “positive”, regardless of 
the diagnostic methods, tended to show a higher correlation among the four key 
symptoms of MD.  There was also a higher correlation between ECochG measures at 
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adjacent frequencies and a lower variation of SP/AP ratios across frequencies in the 
“positive” group as compared with the “negative” group.   
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Chapter Four:  Discussion 
_____________________________________________________________________  
 
 The purpose of this study was to evaluate how ECochG may function as a 
diagnostic tool for MD as compared with the conventional clinical tests.  Findings 
from the present study revealed that the subjective and objective assessment generally 
were in agreement, with a few disagreements on individual diagnoses.  The ECochG 
method was in better agreement with Gibson’s score than the AAO-HNS CHE 
criteria.  This findings in this study also suggested that a diagnosis of MD should not 
be made with a single diagnostic tool in their present form of application.  In addition, 
there was some evidence suggesting that the signs of MD may be distinguishable from 
those of other causes based on the consistency between ECochG measures obtained at 
adjacent frequencies.   
4.1  The Agreement between Diagnostic Tools 
Electrocochleography has been documented in the literature for over 30 years 
as a tool for the diagnosis, assessment, and monitoring of patients with MD (Al-
momani, Ferraro, Gajewski & Ator, 2009).  The AAO-HNS CHE criteria has been 
used as a formalised diagnostic tool from 1972 and since then, has undergone 
revisions in 1985 and 1995 (Committee on Hearing and Equilibrium, 1972; 
Committee on Hearing and Equilibrium, 1985; Members of the Committee on 
Hearing and Equilibrium, 1995).  Both of these diagnostic evaluation tools for MD 
have been clinically used for several years. When compared to each other as 
diagnostic tools, some level of disagreement in diagnosis was found where the patient 
tested “negative” were labelled “definite MD” in AAO-HNS CHE diagnosis or the 
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patient tested “positive” with ECochG measures was given a diagnosis of “negative” 
based on the AAO-HNS CHE criteria.  Using the classification scheme as defined in 
this study, the total between-test agreement was high, but only moderate in the point-
by-point reliability.  A proportion of patients were diagnosed differently by the three 
different diagnostic tools.  However, the true diagnosis of this group of patients, as 
well as all patients of the like, is not available unless a post-mortem takes place after 
the death of the patient. 
There are several differences when using either ECochG or AAO-HNS CHE 
criteria as diagnostic tools for the diagnosis of MD.  The ECochG has been considered 
a specific tool rather than a sensitive tool when using for a diagnosis of MD.  As 
reported by Al-momani et al. (2009), previous literature has shown ECochG to be 
specific to the disorder but not adequately sensitive for evaluating possible MD in a 
patient (with sensitivity estimated around 20-65%).  In an attempt to make ECochG 
more sensitive, Al-momani et al. (2009) measured the SP/AP ratio and compared it to 
the amplitude and duration of the SP and AP.  Using this approach, as opposed to cut-
off scores, they yielded more sensitive ECochG results to MD.  The sensitivity that 
was reported was much higher (92%) than previously estimated.  The findings in this 
study used cut-off scores to obtain a diagnosis, which may have contributed to the 
disagreement with other diagnostic tools.  The findings of this study demonstrated a 
higher consistency of ECochG measures across frequencies, suggesting that the 
sensitivity of the ECochG method may be improved with some modification of the 
rules for discrimination.  Another explanation for the possibly poor sensitivity is the 
nature of the disease itself.  As MD is a fluctuating disease, particularly in the early 
stages, if the test is administered when no symptoms are present, it is unlikely that a 
positive diagnosis will be made.  In other words, repeated measures at different points 
  70 
of time or administering instrumental test around the time when symptoms occur 
would be useful for enhancing the power of the diagnostic tool.  
The AAO-HNS CHE criteria may be more sensitive, but not as specific as the 
objective measure due to the way the assessment categorises patient information and 
the subjective nature of the assessment.  As van de Heyning et al. (1997) described, it 
does not take the length of vertigo attacks into account nor does it measure the 
severity or frequency of the tinnitus and aural pressure.  It also does not take into 
account the severity of the hearing loss.  Not all patients with MD present with all of 
the symptoms in the criteria.  In turn this can lead to an incorrect diagnosis, making 
this method of diagnostic assessment restrictive.   
The findings from this study showed that both ECochG and AAO-HNS CHE 
criteria independently diagnosed a similar number of patients with MD.  This is in 
contrast to the study by Stapleton and Mills (2008), where the AAO-HNS CHE 
criteria diagnosed three times more patients with MD when compared with Prosper 
Ménière’s original description of the disease.  However, Prosper Ménière’s original 
description of the disease is not comparable to ECochG.   
The findings also showed that according to the AAO-HNS CHE criteria, the 
majority of patients had a hearing loss and many of them also had vertigo.  Fewer 
patients presented with tinnitus and aural pressure.  The severity of these symptoms is 
unknown, as none of the three diagnostic assessment tools evaluated in this study 
assessed for this.  It was evident in the results that not all patients presented with all of 
the symptoms, which is part of the difficulty of diagnosing MD.  However, there was 
a tendency for the “positive” group, regardless of the tool used for the classification, 
to exhibit a higher correlation between the severity score of the four key symptoms.  
This is expected as the discrimination of subjective assessment tools is based on the 
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weighing of the accumulating effect.  However, the ECochG diagnosis, which was 
based on the physiological measure instead of the reported symptoms, also yielded the 
same finding, suggesting that the physiological measures may be pertinent and 
sensitive to the changes underlying the fluctuating symptoms. 
Audiometric measures comparing both ECochG and the AAO-HNS CHE 
criteria showed similar results.  A large proportion of total number of patients with 
diagnosed MD had a hearing loss and fewer had normal hearing.  This was expected 
as typical MD symptoms include a hearing loss.  However, there were a number of 
patients with diagnosed MD who had normal hearing.  An explanation for this is that 
the progression of hearing loss has not occurred yet in this population of patients with 
normal hearing.  As Sajjadi & Paparella (2008) has described, a sensorineural hearing 
loss in the affected ear may fluctuate over months and years in those with MD.  Also, 
a large portion of the present sample who had a negative ECochG diagnosis in 
combination with a “possible MD” or “probable MD” AAO-HNS CHE diagnosis had 
normal hearing.  This demonstrates agreement between the two diagnostic tools and 
exhibits hearing loss as a common symptom of Ménière’s disease. 
4.2  Evaluation of Electrocochleography 
As the AAO-NHS-CHE criterion is a subjective diagnostic tool, the 
application of the criteria is susceptible to rating inconsistency.  The physician needs 
to take great care when examining a patient using the subjective method, as it can 
narrow the focus of the assessment and create an inaccurate diagnosis, leading to false 
positives.  The ECochG measures allow for objective assessment, which has the 
advantage over subjective assessment in avoiding rating bias.  However, this method 
of assessment captures only one aspect of the pathophysiological sign associated with 
MD and does not take into consideration the symptoms a patient has, such as vertigo, 
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tinnitus, or aural pressure.  Most importantly, hearing loss can affect the recordings if 
a patient has severe-to-profound hearing loss and their cochlea does not respond to the 
acoustic stimulus presented to them.  On the other hand, the finding that a higher 
correlation between the SP/AP ratios at adjacent frequencies (i.e., 0.5 and 1 kHz, 1 
and 2 kHz, and 2 and 4 kHz) in the “positive” group suggested that the correlations 
between these ECochG measures may discriminate the effect endolymphatic hydrops 
had on the auditory system from other effects.  In other words, the physiological 
measures would be more sensitive if applied with a better discriminating rule, such as 
one that reflects the consistency of the measures between adjacent frequencies. 
Another benefit of ECochG is it takes unilateral and bilateral MD into 
diagnostic consideration, as each ear is assessed independently.  This makes treatment 
for the patient more efficient.  The AAO-NHS-CHE criterion does not assess whether 
the patient has unilateral or bilateral MD.  This has serious considerations when 
treating a patient with symmetrical hearing loss. 
The ECochG is an invasive and more costly test than the AAO-HNS CHE.  
However, the ECochG method provides objective assessment, may be more specific, 
and tests for bilateral MD.  The drawback of ECochG as a diagnostic tool is that if the 
patient has recovered from their symptoms at the time of testing (in the early onset of 
MD), the test will not diagnose them as having MD.  Due to the time it takes for an 
appointment which includes a hearing test, it is not practical to assess a person at an 
initial consultation and there may be a long hospital waiting list for the test to be done.  
It is costly, time inefficient and impractical for the patient, physician, and audiologist 
to repeat this test until they are fully symptomatic of MD.  This may take years after 
onset, and the patient may be in tremendous discomfort over this period if they are 
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waiting on a positive ECochG result.  It is therefore not good practice to use ECochG 
as the only diagnostic evaluation tool for the assessment of MD.   
ECochG is better used as a complementary test in the diagnosis of MD with 
other tests, such as the AAO-HNS CHE criteria or Gibson’s Score.  However, these 
tests are not 100% in agreement with each other on the diagnoses of MD.  Therefore, 
each case should be assessed very carefully, with all tests looked at and an overall 
view of the outcome agreed on by the physician, but not taken on one test alone.  If 
there is doubt, more testing should be done, and other MD diagnostic assessments 
employed, such as MRI. 
It was hypothesized that ECochG would yield more defined results in the 
diagnosis of MD than the AAO-HNS CHE criteria.  The rationale was that ECochG is 
more defined as it objectively yields a positive or negative test result to confirm 
diagnosis while the AAO-HNS CHE criteria gives broader definition as to whether a 
person has MD or not.  ECochG does yield more defined results in the diagnosis of 
MD than that of the AAO-HNS CHE criteria.  However, due to its flaws, it is better 
used in combination with other MD assessment tools rather than used alone in the 
diagnosis of MD.   
Both clicks and tone burst stimuli can be used to elicit an ECochG AER.  Tone 
bursts have been shown to provide more accurate measurements than clicks (Gibson, 
1991).  A study by Ge and Shea (2002) demonstrated that tone bursts had the 
advantage of greater frequency selectivity, making them more accurate at showing the 
degree of hydrops at specific turns of the cochlea.  Gibson (1993) showed that the 1 
kHz tone burst was more reliable than the click for the diagnosis of MD.  The findings 
of the data in this study demonstrated that tone-burst ECochG diagnosed more 
positive ears than clicks.  More tone-burst ECochG diagnoses were made at 1 kHz 
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than the other frequencies tested of 500 Hz, 2 kHz and 4 kHz, making this data in 
agreement with previous research findings.   
4.3  Findings of the Study in Relation to Previous Research 
  On examination of the data, several conclusions can be drawn.  Analysis 
between Gibson’s Score, ECochG, and the AAO-HNS CHE criteria indicated variable 
results below the Gibson Scale cut-off score of 7.  In particular, the findings showed 
disagreement of the diagnoses of MD in the patients for the scores of 2, 3 and 4 
between Gibson’s score, ECochG, and the AAO-HNS CHE criteria.  The result for 
the AAO-HNS CHE diagnosis of “probable MD” is not of concern due to small 
sample size.  Due to the limited literature on diagnostic assessment of Gibson’s score, 
no comparisons can be made, except that of the findings detailed above.   
It has been reported that MD typically occurs unilaterally rather than 
bilaterally (Neely, 2008).  This sample reflects this trend.  However, the findings from 
the current study show a higher percentage of patients tested positive for bilateral MD 
using the ECochG assessment method than the other two methods.  In a study by 
Paparella and Griebe (1984), it was reported that bilateral MD occurred in one in three 
patients.  Half of the patients who developed bilateral MD did so 5 years after the 
onset of the first ear, suggesting that bilateral MD is a natural progression for the 
disease in some people.  This is an important consideration when treatment is being 
offered for the ear presenting with MD symptoms, as every attempt at conservation of 
the non-symptomatic ear should be made.   
The ECochG method and Gibson’s score are the only two diagnostic tools out 
of the three discussed that will take bilateral MD into consideration when making a 
diagnosis.  Therefore, the AAO-HNS CHE could not be assessed for its ability to 
diagnose bilateral MD.  The ECochG method identified a larger amount of patients 
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with bilateral MD than Gibson’s score.  It is noteworthy that the patient identified in 
Gibson’s score was also identified in the electrocochleography evaluation for bilateral 
MD. 
There were several symptomatic differences resulting from the data analysis.  
Almost all patients with a positive ECochG score exhibited hearing loss and vertigo 
and to a lesser extent, tinnitus and aural fullness.  This indicates that hearing loss and 
vertigo are the main symptoms of Ménière’s disease for this sample.  Paparella (1991) 
reported that many patients experience auditory or vestibular symptoms for months or 
years before the onset of other symptoms.  The findings of this study showed that 
symptoms occurred in both isolation and co-occur with other symptoms.   
 The results indicated that many of the patients with a large threshold 
difference between ears in this sample returned a positive electrocochleography result 
and a “definite MD” AAO-HNS CHE diagnosis.  This may suggest that a 20 dB HL 
or greater difference between audiometric thresholds should be referred to an 
Otolaryngologist for evaluation of asymmetric hearing thresholds.  In this sample 
asymmetric hearing loss in combination with vertigo were the dominant symptoms of 
MD.   
Demographic data, such as gender and age of onset in populations of 
Ménière’s disease are essential to compare with other populations.  The literature does 
not indicate that Ménière’s disease is more common in males (Paparella, 1991).  
However, the findings in this study indicate strongly that more males have Ménière’s 
disease, with almost twice as many males testing positive to electrocochleography as 
female.  
The common age for acquiring Ménière’s disease is approximately 40-50 
years of age (Paparella et al., 1991; Vrabec et al., 2007).  This sample shows most of 
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the patients with “definite MD” are between the ages of 41 and 80, making this 
sample a much older population of those with MD.   
4.4  Clinical Implications  
 Findings from the current study offer some clinical implications for the 
assessment of Ménière’s disease.  The current study confirms that there is a slight 
disagreement in the diagnoses of patients with MD between the diagnostic 
assessments of ECochG and the AAO-HNS CHE criteria; however they are generally 
in agreement.  As a result, it suggests that ECochG cannot be used alone in the 
diagnosis of MD.   
 ECochG used in combination with another assessment tools for the diagnosis 
of MD, such as the AAO-HNS CHE criteria or Gibson’s score is beneficial.  If 
agreement is shown, then it is likely that the patient has MD, if there is a 
disagreement, then the case needs to be looked at closely, and other assessment tools 
employed.  
4.5  Limitations of the Study and Future Direction 
There are a number of limitations to the generalisation of the present findings.  
Firstly, although the number of medical records reviewed in the study was high, a 
total review of the entire patient list assessed for Ménière’s disease at Christchurch 
Public Hospital, Christchurch, New Zealand since the commencement of ECochG 
testing at that hospital may be more representative of clinical population seen in the 
Canterbury area.  Future studies may incorporate the rest of the assessed population to 
understand MD trends in Canterbury, New Zealand.  This may in turn be extended to 
other regions of the country to allow for further assessment of the disease.   
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In addition, future studies involving the analysis of progression of hearing loss 
in the patients who presented with normal hearing in this study and were diagnosed 
with MD would be of interest.  This would chart the progression that the hearing loss 
takes over the years and possibly a change in diagnosis, yielding information 
regarding the duration of the development from some symptoms to complete MD 
symptoms in this population.   
Due to the limited literature on diagnostic assessment of Gibson’s score, 
research involving the outcomes of this score is needed in order to compare it with 
other diagnostic methods that are available.   
Furthermore without a clinically accepted “gold standard” for the assessment 
of MD, it is challenging to make the diagnosis or assess the predictive power of a 
diagnostic tool.  MRI imaging is developing in Christchurch and may lead to a more 
robust assessment of MD. 
4.6  Conclusion 
This study highlighted some important points related to the assessment of 
Ménière’s disease using different approaches.  Firstly, it can be concluded that the 
three diagnostic assessment tools of electrocochleography, the AAO-HNS CHE 
criteria and Gibson’s score are generally in agreement regarding a patient’s diagnosis 
of Ménière’s disease.  Secondly, ECochG is an effective diagnostic tool but it should 
not be used as the sole assessment tool for the diagnosis of MD as its effectiveness 
may be dependent on the patient having full symptoms of the disease at the time of 
testing.  
It is important that professionals are aware of the disagreement between these 
three tests and the advantage of using ECochG, in combination with another 
assessment tools, for the diagnosis of MD.  The finding of the consistency between 
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ECochG measures across frequencies needs further investigation.  Development in the 
area of MRI may provide better parallel validation for the diagnostic tools and open 
up this area of research extensively. 
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MRI Study by J. Hornibrook, M. Coates, G. Goh & P. Bird 
Within the practice of J. Hornibrook, the following two cases were reviewed for 
Ménière’s disease (MD) using electrocochleography (ECochG) and the AAO-HNS 
CHE criteria (Members of the Committee on Hearing and Equilibrium, 1995).  Due to 
limited spatial resolution of 1.5 Tesla scanners, MRI studies of the inner ear have not 
been possible.  Newer scanners with a greater magnetic strength make imaging of the 
inner ear now possible.  Using a 3 Tesla scanner, endolymphatic hydrops has been 
demonstrated (Nakashima et al., 2009).   
 
Procedure 
MRI scans were conducted on two patients.  The MRI used a 3 Tesla Magnet 
(General Electric HDX).  Twenty-four hours prior to the scan, Multihance gadolinium 
1.6ml in 10 ml saline was infused into the right middle ear of both patients over a 
duration of 45 minutes.  
 
Patients 
Patient 1 was an 80 year old male with vertigo attacks, mild right ear hearing loss and 
no aural symptoms.  He obtained a negative ECochG result and a “possible MD” 
AAO HNS CHE criteria diagnosis for Ménière’s disease, with an overall diagnosis 
concluding that his symptoms were not MD. 
Patient 2 was a 46 year old male with a two year history of vertigo attacks, 
progressive hearing loss in the right ear, tinnitus and aural fullness.  He obtained a 
  86 
positive ECochG result and a “definite MD” AAO HNS CHE criteria diagnosis for 
Ménière’s disease, with an overall diagnosis concluding that his symptoms were MD. 
Results 
Patient 1:  Normal inner ear, no endolymphatic hydrops 
 
Figure 1.  Perilymph sequence.  The cochlea, vestibule and one semicircular canal are 
labelled.  P= perilymph, E= endolymph.  Brightly enhancing perilymph predominates 
in all areas.  In the cochlea, a normal narrow endolymphatic compartment is seen.  No 
hydrops. 
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Figure 2.  Endolymph sequence.  The basal turn of the cochlea, with normal 
endolymphatic compartment.  No hydrops. 
 
Patient 2:  Ménière’s disease, endolymphatic hydrops present 
 
Figure 3.  Perilymph sequence.  A significant enlargement (33-50%) of the 
endolymphatic compartment in the cochlea.  In the vestibule and semicircular canal 
endolymphatic hydrops (>50%) has displaced almost all perilymph.  
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Figure 4.  Endolymph sequence.  An enlargement of the endolymphatic compartment 
in the cochlea.  Endolymph fills the vestibule.  
 
Concluding Remarks 
These MRI images show a normal inner ear (Patient1) and an abnormal ear (Patient 2) 
resulting in endolymphatic hydrops, Ménière’s disease.  This result was in total 
agreement with the two pre-diagnostic assessment tools of ECochG and the AAO-
HNS CHE criteria.  With more research, this tool may have a new role in the 
diagnosis of MD and other inner ear conditions.  
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Health Research Council approval letter 
University of Canterbury Human Ethics Committee approval letter 
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4 March 2009 
 
Catherine Kalin 
Department of Communication Disorders 
University of Canterbury 
Private Bag 4800 
Christchurch 
 
 
Dear Catherine Kalin, 
 
The evaluation of electrochochleography as a diagnostic tool for Meneire’s 
Disease 
Investigators: C Kalin, Dr E Lin (supervisor), Prof J Hornibrook, Dr G O’Beirne 
Ethics ref: URA/09/06/EXP 
 
The above study has been given ethical approval by one member and the 
Chairperson of the Upper South A Regional Ethics Committee.   
 
Final Report  
The study is approved until 4 March 2010.  A final report is required at the end of the 
study and a report form to assist with this is available at 
http://www.newhealth.govt.nz/ethicscommittees.  If the study will not be completed as 
advised, please forward a report form and an application for extension of ethical 
approval one month before the above date.     
 
Amendments 
It is also a condition of approval that the Committee is advised if the study does not 
commence, or is altered in any way, including all documentation. 
 
Please quote the above ethics committee reference number in all correspondence. 
 
It should be noted that Ethics Committee approval does not imply any resource 
commitment or administrative facilitation by any healthcare provider within whose 
facility the research is to be carried out.  The organisation may specify their own 
processes regarding notification or approval. 
 
We wish you well with your study. 
 
Yours sincerely 
 
 
 
 
 
 
Alieke Dierckx 
Upper South A Ethics Committee Administrator 
Alieke_dierckx@moh.govt.nz  
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Ref:  HEC 2009/LR/10  
 
 
 
 
31 March 2009 
 
 
Catherine Kalin 
Department of Communication Disorders 
UNIVERSITY OF CANTERBURY 
 
 
Dear Catherine  
 
Thank you for forwarding to the Human Ethics Committee a copy of the low risk 
application you have recently made for your research proposal “The evaluation of 
electrocochleography as a diagnostic tool for Ménière’s disease.”   
 
I am pleased to advise that this application has been reviewed and I confirm support 
of the Department’s approval for this project, subject to final approval from the 
Health & Disability Ethics Committee.  I will be pleased to receive a copy of their 
final approval when this has been granted. 
 
With best wishes for your project.  
 
 
Yours sincerely 
 
 
 
 
 
Dr Michael Grimshaw 
Chair, Human Ethics Committee 
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The COV measures for patients retested at different points of time, showing the 
patient’s gender and age and the ECochG diagnosis on the day in the legend box (e.g., 
“F77:  neg-neg” means the subject is a 77 year-old female who was diagnosed as 
“negative” on both visits with ECochG measures.) 
Time from initial visit (in months)
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